ReviewJournal of nanobiotechnology2025
2D nanomaterial-triggered ferroptosis in cancer therapy.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy faces significant challenges due to the resistance of traditional apoptosis-based treatments. Ferroptosis, an iron-dependent, lipid peroxidation-driven form of programmed cell death, has emerged as a novel therapeutic strategy owing to its unique metabolic regulation mechanisms. However, conventional small-molecule ferroptosis inducers suffer from poor targeting and rapid metabolism. The integration of nanotechnology provides innovative solutions for precise ferroptosis modulation. Among various nanomaterials, two-dimensional (2D) nanomaterials stand out due to their distinctive physicochemical properties and multifunctionality, making them widely studied in ferroptosis-mediated cancer therapy. In this review, we first outline the development, physiological mechanisms, detection markers, and common methodologies of ferroptosis, while highlighting the current challenges in ferroptosis-related cancer therapies. Second, we discuss the general principles of 2D materials in inducing ferroptosis, emphasizing how these platforms enhance ferroptosis efficacy. Third, we classify and elaborate on different types of 2D materials that induce ferroptosis in tumor cells. Finally, we present future perspectives in this field. We hope this review will facilitate the rational design of 2D materials for ferroptosis induction and pave the way for broader biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.